J Korean Diabetes.  2025 Mar;26(1):28-31. 10.4093/jkd.2025.26.1.28.

Injectable Drugs in Diabetes Treatment: Insulin versus Incretin

• Ahn KH

• KMID: 2567088
• DOI: http://doi.org/10.4093/jkd.2025.26.1.28

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by hyperglycemia. While lifestyle modifications and oral medications are initial treatments, many patients require injectable therapies like insulin and incretin-based drugs. Insulin therapy, a cornerstone treatment for T2DM, can effectively control blood sugar but is associated with hypoglycemia and weight gain. Incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists offer improved glycemic control, weight loss, and reduced cardiovascular risk. Recent studies have shown the superiority of incretin-based therapies over basal insulin. Among these, GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonists like tirzepatide have demonstrated significant weight loss and improved glycemic control. Selection of injectable therapy should be individualized based on factors like glycemic goals, cardiovascular risk, hypoglycemia risk, and patient preference. While insulin remains a useful option, incretin-based therapies, especially newer agents, offer promising therapeutic benefits for many patients with T2DM.

Keyword

Diabetes mellitus, type 2; Glucagon like peptide 1; Incretins; Insulin; Tirzepatide

Reference

1.Choi JH., Lee KA., Moon JH., Chon S., Kim DJ., Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023. 47:575–94.

2.Rahman MS., Hossain KS., Das S., Kundu S., Adegoke EO., Rahman MA, et al. Role of insulin in health and disease: an update. Int J Mol Sci. 2021. 22:6403.

3.Tan Q., Akindehin SE., Orsso CE., Waldner RC., DiMarchi RD., Müller TD, et al. Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol (Lausanne). 2022. 13:838410.

4.Oh S. New therapeutics for diabetes using incretin hormone. Korean J Med. 2011. 80:625–34.

5.Nauck MA., Mirna AEA., Quast DR. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: an update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Diabetes Obes Metab. 2023. 25:1361–71.

6.Jastreboff AM., Aronne LJ., Ahmad NN., Wharton S., Connery L., Alves B., SURMOUNT-1 Investigators, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. 387:205–16.

7.Oh TJ. GLP-1/GIP receptor agonists: mechanism of action of tirzepatide. J Korean Diabetes. 2024. 25:76–81.

8.Lee I., Kang ES. Injectable therapy for diabetes mellitus: glucagon-like peptide-1 receptor agonist. J Korean diabetes. 2019. 20:149–56.

9.Kim HJ. Recent updates on glucagon-like peptide 1 receptor agonist. J Korean Diabetes. 2021. 22:126–33.